NCT04891770: A reported trial by Gilead Sciences
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT04891770 |
|---|---|
| Title | A Phase 2a, Open-Label Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Aug. 14, 2021 |
| Completion date | Jan. 23, 2024 |
| Required reporting date | Jan. 23, 2027, midnight |
| Actual reporting date | July 7, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |